Medicaid
Patients could face fewer hurdles for cheaper drugs
The measure would bar extra red tape such as prior authorization and step therapy when a generic or biosimilar is the lower-cost option. It also says those drugs should be shown on plan formularies with more favorable out-of-pocket costs.
For families filling prescriptions, the point is simple: if a cheaper drug can do the same job, the plan should not make it harder to get. The bill also keeps pharmacists on firmer ground when they substitute interchangeable biosimilars.
- Lower-cost generics and biosimilars get priority in coverage rules.
- Plans cannot add extra barriers like prior authorization or step therapy for the cheaper option.
- Pharmacists get clearer authority to substitute interchangeable biosimilars.
- The law reaches state employee and Medicaid-linked managed care plans.
- For patients in New Jersey, the practical change is simple: if a cheaper generic or biosimilar can replace a brand-name drug, the insurance rules are supposed to stop getting in the way
For New Jersey patients filling prescriptions, the bill would make it harder for insurers to block a cheaper drug that works the same way as a brand-name medicine. It would require health plans to cover approved generics and biosimilars with better cost sharing and no added prior authorization or step-therapy hurdles.
The same basic approach applies to biosimilars, the highly similar follow-on versions of biological drugs. The coverage rules reach state employee health plans and Medicaid-linked managed care plans, so the change is not limited to one corner of the insurance market.
At the pharmacy counter
The bill also revises what pharmacists can do when a prescriber has not blocked substitution. If the biosimilar is interchangeable or therapeutically equivalent, the pharmacist shall substitute it for the prescribed reference product.
That swap is not supposed to happen in the shadows. Pharmacists must record the product name and manufacturer on the label and in the dispensing record, and the law says they face no greater liability for dispensing the biosimilar than for the original drug.
The rulebook behind the savings
The law does leave room for medical judgment. A provider can still object for an individual patient, and plans are not required to keep covering a brand drug once a lower-cost substitute is available. They can also drop coverage if they decide a drug is no longer medically appropriate or cost-effective.
Available key vote records show the bill advanced without recorded no votes.